Abstract:Future PDTOs are potent models for basic research and clinical uses. Due to its editability and biobanking capability, PDTOs are powerful in vitro models for personalized drug screening, new drug discovery, and precision medicine. Background Organoid technology is an emerging and rapidly growing field that shows promise in studying organ development and screening therapeutic regimens. Although organoids have been proposed for a decade, concerns exist, including batch‐to‐batch variations, lack of the native microenvironment and clinical applicability. Main body The concept of organoids has derived patient‐derived tumour organoids (PDTOs) for personalized drug screening and new drug discovery, mitigating the risks of medication misuse. The greater the similarity between the PDTOs and the primary tumours, the more influential the model will be. Recently, 'tumour assembloids' inspired by cell‐coculture technology have attracted attention to complement the current PDTO technology. High‐quality PDTOs must reassemble critical components, including multiple cell types, tumour matrix, paracrine factors, angiogenesis and microorganisms. This review begins with a brief overview of the history of organoids and PDTOs, followed by the current approaches for generating PDTOs and tumour assembloids. Personalized drug screening has been practised; however, it remains unclear whether PDTOs can predict immunotherapies, including immune drugs (e.g. immune checkpoint inhibitors) and immune cells (e.g. tumour‐infiltrating lymphocyte, T cell receptor‐engineered T cell and chimeric antigen receptor‐T cell). PDTOs, as cancer avatars of the patients, can be expanded and stored to form a biobank. Conclusion Fundamental research and clinical trials are ongoing, and the intention is to use these models to replace animals. Pre‐clinical immunotherapy screening using PDTOs will be beneficial to cancer patients. Key Points The current PDTO models have not yet constructed key cellular and non‐cellular components. PDTOs should be expandable and editable. PDTOs are promising preclinical models for immunotherapy unless mature PDTOs can be established. PDTO biobanks with consensual standards are urgently needed.

Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy

Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy

Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy

Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology

Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy

Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment

Patient-derived organoids in precision cancer medicine

Patient‐derived Cancer Organoids for Drug Screening: Basic Technology and Clinical Application

Organoids: new frontiers in tumor immune microenvironment research

Patient-derived Organoids in Translational Oncology and Drug Screening

The use of organoids in creating immune microenvironments and treating gynecological tumors

Recent advances in patient‐derived tumor organoids for reconstructing TME of head and neck cancer

The future of cancer therapy: exploring the potential of patient-derived organoids in drug development

Cancer organoids: A platform in basic and translational research

Organoid models of the tumor microenvironment and their applications

Organoids as an Enabler of Precision Immuno-Oncology

Patient-derived Immunocompetent Tumor Organoids: A Platform for Chemotherapy Evaluation in the Context of T-cell Recognition

Immune organoids: from tumor modeling to precision oncology

Patient‐derived Immunocompetent Tumor Organoids: A Platform for Chemotherapy Evaluation in the Context of T‐cell Recognition

Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment